NOF urges care on Acomplia hopes
The president of the National Obesity Forum this week warned that drugs giant Sanofi-Aventis faces a PR challenge to manage growing expectations for its pre-launch drug Acomplia – described by the press last week as a ‘wonder drug’ that will ‘treat obesity, help smokers quit and tackle cholesterol levels’.
Sign in to continue
Need to activate your subscription?
Domain/Group Subscriptions
Click here >>
Individual Subscriptions
Click here >>
Need to activate your Subscription
Company Wide Subscriptions
Click here >>
UK Individual Subscribers
Click here >>